Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.
Mario Enrico CanonicoCecilia C Low WangJudith HsiaE Sebastian DebusMark R NehlerManesh R PatelSonia S AnandJoseph YcasWarren H CapellEva MuehlhoferLloyd P HaskellScott D BerkowitzRupert BauersachsMarc P BonacaPublished in: Journal of the American College of Cardiology (2024)
Patients with PAD after lower extremity revascularization meeting fragile criteria are at higher risk of ischemic complications and bleeding. Rivaroxaban reduces ischemic risk and increases bleeding regardless of frailty status. These data may assist in personalization of antithrombotic therapy in fragile population.
Keyphrases
- atrial fibrillation
- low dose
- end stage renal disease
- percutaneous coronary intervention
- venous thromboembolism
- ejection fraction
- chronic kidney disease
- coronary artery bypass grafting
- pulmonary embolism
- newly diagnosed
- peritoneal dialysis
- ischemia reperfusion injury
- high dose
- prognostic factors
- antiplatelet therapy
- type diabetes
- electronic health record
- big data
- machine learning
- coronary artery disease
- stem cells
- bone marrow
- cardiovascular events
- mesenchymal stem cells
- deep learning
- smoking cessation
- data analysis